Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2007

View Archived Issues

Six-plasmid HIV-1 DNA vaccine candidate advances to phase II

Bavarian Nordic reports on U.S. developments

SBIR grant supports OligoMerix's work in Alzheimer's disease

Recent Boehringer Ingelheim patent reports novel analgesic agents for migraine

Sphingozumab effective in animal models of laser-induced CNV

SQ-109 for TB completes phase Ia trial

CyDex licenses Captisol enabling technology to Sunesis for Aurora kinase inhibitor

Rare Disease Therapeutics to market Cystadane in U.S. and Canada

Peptech and Evogenix to merge

Viragen to end collaboration with Memorial Sloan-Kettering on VG-101

Ganaxolone studied for adult partial onset seizures in new phase IIb trial

Affitech and Roche sign antibody research and licensing agreement

Brazilian Government issues compulsory license on Stocrin

KAI-1455 begins phase I trial for prevention of ischemic injury

Recent patents describe new treatment options for diabetes

Novel therapeutic agents for cardiovascular disorders reported in recent patent literature

Ista withdraws European application for Vitragan

Enrollment open in phase I study of new obesity candidate trodusquemine

Aastrom cleared for phase III study of bone repair cell product in osteonecrosis

The mTOR inhibitor QLT-0447 potently suppresses CNV in vivo

Topically applied TG-101095 shows promise in a murine laser-induced CNV model

Gentamicin-induced stop codon readthrough shows benefit in a retinitis pigmentosa rat model

Q1 progress at BioMarin

Enjuvia receives two new FDA approvals

Taxus Express2 paclitaxel-eluting coronary stent system launched in Japan

E.U. approval for pandemic influenza vaccine Focetria

Pergoveris recommended for E.U. approval

Circadian recommended for E.U. approval in primary insomnia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...